|
41 Companies |
|
50 Products |
|
50 Products |
|
53 Mechanisms of Action |
|
1 Trial |
|
299 News |
|
| «123456» |
- dexamethasone / Generic mfg.
Trial primary completion date: Dexamethasone Irrigation of the Parotid Glands in Primary Sj (clinicaltrials.gov) - Jun 19, 2014
P2, N=20, Recruiting, Sponsor: National Institute of Dental and Craniofacial Research (NIDCR)
Trial primary completion date: Jun 2014 --> Jun 2015
- Trial completion: Evaluation of Therapeutic Effect of Bandage Contact Lenses ( BCL) on Dry Eye Caused by Sjogren's Syndrome (clinicaltrials.gov) - Jun 18, 2014
P=N/A, N=64, Completed, Sponsor: Jinyang Li
Trial primary completion date: Jun 2014 --> Jun 2015 Enrolling by invitation --> Completed
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Combination therapy, Metastases: Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jun 12, 2014
P1/2, N=66, Completed, Sponsor: National Cancer Institute (NCI)
Enrolling by invitation --> Completed Trial primary completion date: Jul 2008 --> Oct 2007
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Metastases: Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jun 9, 2014
P1/2, N=66, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2008 --> Oct 2007 Recruiting --> Completed
- Trial initiation date: Effects of Sustained Reading on the Ocular Surface (clinicaltrials.gov) - May 22, 2014
P=N/A, N=30, Recruiting, Sponsor: University of Rochester
Recruiting --> Completed Initiation date: Feb 2014 --> Mar 2014
- Enrollment open: Effects of Sustained Reading on the Ocular Surface (clinicaltrials.gov) - May 22, 2014
P=N/A, N=30, Recruiting, Sponsor: University of Rochester
Initiation date: Feb 2014 --> Mar 2014 Not yet recruiting --> Recruiting
- Trial completion date: SMILE: Study of the Effectiveness of Cevimeline on Oral Health in Patients With Radiation Induced Xerostomia (clinicaltrials.gov) - May 20, 2014
P4, N=54, Completed, Sponsor: American Academy of Otolaryngology-Head and Neck Surgery Foundation
Not yet recruiting --> Recruiting Trial completion date: Nov 2008 --> Aug 2009
- Enrollment change: SMILE: Study of the Effectiveness of Cevimeline on Oral Health in Patients With Radiation Induced Xerostomia (clinicaltrials.gov) - May 20, 2014
P4, N=54, Completed, Sponsor: American Academy of Otolaryngology-Head and Neck Surgery Foundation
Trial completion date: Nov 2008 --> Aug 2009 N=108 --> 54
- Trial completion: SMILE: Study of the Effectiveness of Cevimeline on Oral Health in Patients With Radiation Induced Xerostomia (clinicaltrials.gov) - May 20, 2014
P4, N=54, Completed, Sponsor: American Academy of Otolaryngology-Head and Neck Surgery Foundation
N=108 --> 54 Recruiting --> Completed
- Biomarker, Enrollment open: Salivary Biomarkers for Sj (clinicaltrials.gov) - May 18, 2014
P=N/A, N=420, Recruiting, Sponsor: University of California, Los Angeles
Recruiting --> Completed Not yet recruiting --> Recruiting
- cisplatin / Generic mfg., docetaxel / Generic mfg., sorafenib / Generic mfg.
Trial initiation date, Combination therapy, Metastases: Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - May 11, 2014
P1/2, N=41, Recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
Not yet recruiting --> Recruiting Initiation date: Jan 2014 --> Apr 2014
- cisplatin / Generic mfg., docetaxel / Generic mfg., sorafenib / Generic mfg.
Enrollment open, Combination therapy, Metastases: Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - May 11, 2014
P1/2, N=41, Recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
Initiation date: Jan 2014 --> Apr 2014 Not yet recruiting --> Recruiting
- cyclosporin A microemulsion / Generic mfg.
Trial primary completion date: CYPRESS: Low Dose Cyclosporin A in Primary Sjögren Syndrome (clinicaltrials.gov) - May 6, 2014
P2, N=30, Active, not recruiting, Sponsor: Charite University, Berlin, Germany
Not yet recruiting --> Recruiting Trial primary completion date: Jan 2014 --> Oct 2014
- cyclosporin A microemulsion / Generic mfg.
Trial completion date: CYPRESS: Low Dose Cyclosporin A in Primary Sjögren Syndrome (clinicaltrials.gov) - May 6, 2014
P2, N=30, Active, not recruiting, Sponsor: Charite University, Berlin, Germany
Trial primary completion date: Jan 2014 --> Oct 2014 Trial completion date: Mar 2014 --> Oct 2014
- cyclosporin A microemulsion / Generic mfg.
Enrollment closed: CYPRESS: Low Dose Cyclosporin A in Primary Sjögren Syndrome (clinicaltrials.gov) - May 6, 2014
P2, N=30, Active, not recruiting, Sponsor: Charite University, Berlin, Germany
Trial completion date: Mar 2014 --> Oct 2014 Recruiting --> Active, not recruiting
- ||||| Priorix (MMR vaccine) / GSK
Trial initiation date: Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older (clinicaltrials.gov) - Apr 30, 2014
P3, N=1000, Not yet recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Initiation date: May 2014 --> Jun 2014
- acetylcysteine solution / Generic mfg.
Enrollment open: Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy (clinicaltrials.gov) - Apr 30, 2014
P=N/A, N=36, Recruiting, Sponsor: Mayo Clinic
Initiation date: May 2014 --> Jun 2014 Not yet recruiting --> Recruiting
- ||||| Xeomin (incobotulinumtoxinA) / Merz Pharma
Trial initiation date: SIAXI: Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions (clinicaltrials.gov) - Apr 28, 2014
P3, N=180, Recruiting, Sponsor: Merz Pharmaceuticals GmbH
Not yet recruiting --> Recruiting Initiation date: Mar 2014 --> Apr 2014
- |||||| Xeomin (incobotulinumtoxinA) / Merz Pharma
Enrollment open: SIAXI: Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions (clinicaltrials.gov) - Apr 28, 2014
P3, N=180, Recruiting, Sponsor: Merz Pharmaceuticals GmbH
Initiation date: Mar 2014 --> Apr 2014 Not yet recruiting --> Recruiting
- Clinical: Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy (clinicaltrials.gov) - Apr 23, 2014
P=N/A, N=36, Recruiting, Sponsor: Mayo Clinic
- Avastin (bevacizumab) / Roche
Enrollment change, Adverse events: Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer (clinicaltrials.gov) - Apr 20, 2014
P2, N=11, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting N=16 --> 11
- Clinical: Examining the Immunological Process of Autoimmune Patients (clinicaltrials.gov) - Apr 15, 2014
P=N/A, N=200, Not yet recruiting, Sponsor: University of Florida
- Enrollment change: Exploratory Study in the Relief of Drug-induced Xerostomia Associated With Hyposialia (clinicaltrials.gov) - Apr 13, 2014
P=N/A, N=40, Completed, Sponsor: Pierre Fabre Medicament
N=16 --> 11 N=24 --> 40
- | Trial completion: Exploratory Study in the Relief of Drug-induced Xerostomia Associated With Hyposialia (clinicaltrials.gov) - Apr 13, 2014
P=N/A, N=40, Completed, Sponsor: Pierre Fabre Medicament
N=24 --> 40 Recruiting --> Completed
- | dovitinib (TKI258) / Allarity Therap, Oncoheroes
Enrollment closed, Metastases: DOVE: A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands (clinicaltrials.gov) - Apr 13, 2014
P2, N=20, Active, not recruiting, Sponsor: Ontario Clinical Oncology Group (OCOG)
Recruiting --> Completed Recruiting --> Active, not recruiting
- Recentin (cediranib) / AstraZeneca
Enrollment change, Monotherapy, Metastases: Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer (clinicaltrials.gov) - Apr 8, 2014
P2, N=19, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting N=40 --> 19
- Enrollment open: NeutraSal Treatment for Xerostomia in OSAS Patients Using CPAP Therapy (clinicaltrials.gov) - Apr 3, 2014
P=N/A, N=32, Recruiting, Sponsor: Medical University of South Carolina
N=40 --> 19 Not yet recruiting --> Recruiting
- Clinical: Efficacy of Intravenous Glyco-P® in Patients Undergoing Procedure That Require Anesthesia Service (clinicaltrials.gov) - Apr 1, 2014
P=N/A, N=65, Completed, Sponsor: Mahidol University
- |||||||||| Xeomin (incobotulinumtoxinA) / Merz Pharma
New P3 trial: SIAXI: Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions (clinicaltrials.gov) - Mar 17, 2014
P3, N=180, Recruiting, Sponsor: Merz Pharmaceuticals GmbH
- | sorafenib / Generic mfg.
Trial completion, Metastases: S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=40, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | ispinesib (SB-715992) / Cytokinetics
Trial completion, Metastases: SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=33, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | lapatinib / Generic mfg.
Trial completion, Metastases: Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers (clinicaltrials.gov) - Feb 22, 2014
P2, N=67, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion, Metastases: Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors (clinicaltrials.gov) - Feb 22, 2014
P1, N=30, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | bortezomib / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion, Metastases: Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck (clinicaltrials.gov) - Feb 22, 2014
P2, N=37, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | erlotinib / Generic mfg., docetaxel / Generic mfg.
Trial completion, Combination therapy, Metastases: Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=45, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap
Trial completion, Metastases: Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck (clinicaltrials.gov) - Feb 22, 2014
P2, N=144, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | erlotinib / Generic mfg.
Trial completion: Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction (clinicaltrials.gov) - Feb 22, 2014
P1, N=75, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Suspended --> Completed
- | Leukine (sargramostim) / Partner Therap
Trial completion, Metastases: Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer (clinicaltrials.gov) - Feb 22, 2014
P1, N=48, Completed, Sponsor: National Cancer Institute (NCI)
Suspended --> Completed Suspended --> Completed
- | Avastin (bevacizumab) / Roche
Trial completion, Metastases: Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer (clinicaltrials.gov) - Feb 22, 2014
P1, N=39, Completed, Sponsor: National Cancer Institute (NCI)
Suspended --> Completed Active, not recruiting --> Completed
- MK-2206 / Merck (MSD)
Enrollment change, Metastases: Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma (clinicaltrials.gov) - Feb 20, 2014
P2, N=15, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=41 --> 15
- MK-2206 / Merck (MSD)
Enrollment closed, Metastases: Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma (clinicaltrials.gov) - Feb 20, 2014
P2, N=15, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=41 --> 15 Suspended --> Active, not recruiting
- | Herceptin (trastuzumab) / Roche
Trial completion: Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu (clinicaltrials.gov) - Feb 19, 2014
P1, N=15, Completed, Sponsor: National Cancer Institute (NCI)
Suspended --> Active, not recruiting Active, not recruiting --> Completed
- New P2 trial: Laser Therapy to Treat the Dry Mouth of Sjogren's Syndrome (clinicaltrials.gov) - Feb 18, 2014
P2, N=34, Recruiting, Sponsor: Federal University of São Paulo
- | New P2 trial: A Randomized Controlled Trial Evaluating the Effectiveness of a Salvia-based Mouthwash in Palliative Care (clinicaltrials.gov) - Feb 18, 2014
P2, N=88, Not yet recruiting, Sponsor: Lovisenberg Diakonale Hospital
- ||||||| ProQuad (measles, mumps, rubella and varicella virus vaccine live) / Merck (MSD)
Trial completion: Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027) (clinicaltrials.gov) - Feb 10, 2014
P3, N=1413, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment change: Efficacy Study of a Ginger and Cardamom Gelatin for Xerostomy in Terminally Ill Patients (clinicaltrials.gov) - Feb 9, 2014
P=N/A, N=32, Completed, Sponsor: Fundacio Institut Catala de l'Envelliment
Active, not recruiting --> Completed N=40 --> 32
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (clinicaltrials.gov) - Feb 9, 2014
P1/2, N=43, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=40 --> 32 N=55 --> 43
- Trial completion: Efficacy Study of a Ginger and Cardamom Gelatin for Xerostomy in Terminally Ill Patients (clinicaltrials.gov) - Feb 9, 2014
P=N/A, N=32, Completed, Sponsor: Fundacio Institut Catala de l'Envelliment
N=55 --> 43 Recruiting --> Completed
- |||||||||| Priorix (MMR vaccine) / GSK
New P3 trial: Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older (clinicaltrials.gov) - Feb 6, 2014
P3, N=1000, Not yet recruiting, Sponsor: GlaxoSmithKline
- ||||| New P4 trial: A New Oral salIvary equivAlent Compared to Two moisturizinG Mouth sprAys in Patients With xeRostomiA: NIAGARA Study (clinicaltrials.gov) - Jan 27, 2014
P4, N=210, Completed, Sponsor: Unither Pharmaceuticals, France